TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Niagen Bioscience ( (NAGE) ) has provided an announcement.
On November 6, 2025, Niagen Bioscience announced that its Board of Directors approved a share repurchase program authorizing the company to buy back up to $10 million of its common stock over the next 24 months. This move reflects the company’s belief in its investment value and represents a strategic use of capital. The repurchases will be conducted in compliance with applicable laws and market conditions, and the program may be modified or terminated at any time. This initiative is expected to impact the company’s market positioning and shareholder value positively.
The most recent analyst rating on (NAGE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
Niagen Bioscience’s strong financial performance and positive earnings call are key strengths, indicating robust growth and strategic positioning. However, technical indicators reflect bearish momentum, and the stock’s high valuation may deter some investors. Regulatory challenges and pricing strategies also pose potential risks.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly known as ChromaDex Corp., is a leading global authority in NAD+ science and healthy-aging research. The company is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. Niagen Bioscience is renowned for its state-of-the-art laboratories, rigorous scientific protocols, and collaborations with leading research institutions worldwide. Its product portfolio includes Niagen®, a patented nicotinamide riboside (NR) supplement, and Tru Niagen®, the top-selling NAD+ boosting oral supplement in the United States.
Average Trading Volume: 1,101,892
Technical Sentiment Signal: Hold
Current Market Cap: $554.7M
Learn more about NAGE stock on TipRanks’ Stock Analysis page.